PHILADELPHIA — The members of the American Association for Cancer Research (AACR) have elected five members to serve on the AACR Board of Directors for the 2016-2019 term and four members to serve on the nominating committee for the 2016-2018 term. They will begin their terms at the AACR Annual Meeting 2016, to be held in New Orleans, April 16-20.
The following five scientists were elected to the board of directors:
Alan Ashworth, PhD, president, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF); senior vice president for cancer services, UCSF Health; professor of medicine, Division of Hematology/Oncology, Department of Medicine; and E. Dixon Heise distinguished professor in oncology, UCSF;
Dafna Bar-Sagi, PhD, professor of medicine and biochemistry and molecular pharmacology; senior vice president and vice dean for science; and chief scientific officer, New York University School of Medicine;
Karen M. Cichowski, PhD, associate professor of medicine; co-director of Cancer Biology Graduate Program; Ludwig Center Investigator, Harvard Medical School, Boston; co-director, Landry Cancer Biology Consortium, Harvard University, Cambridge, Massachusetts; director, Center for Targeted Cancer Therapies, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston; associate director of Planning and Evaluation and member, Dana-Farber/Harvard Cancer Center;
Levi A. Garraway, MD, PhD, associate professor of medicine and member of BBS Graduate Program, Harvard Medical School, Boston; active staff, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; associate physician of medicine, Brigham and Women’s Hospital, Boston; associate member, Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts; senior associate member and institute member, Broad Institute; co-leader, Cancer Genetics Program, Dana-Farber/Harvard Cancer Center; co-leader, Melanoma Program, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; director, Center for Cancer Precision Medicine, Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Broad Institute; and
Antoni Ribas, MD, PhD, professor of medicine, surgery, and molecular and medical pharmacology, University of California, Los Angeles (UCLA); director, Tumor Immunology Program, UCLA Jonsson Comprehensive Cancer Center.
The following four scientists were elected to the nominating committee:
Frederick W. Alt, PhD, director, Program in Cellular and Molecular Medicine, Boston Children’s Hospital; professor of genetics and pediatrics, Harvard Medical School, Boston; investigator, Howard Hughes Medical Institute, Boston Children’s Hospital;
Lisa M. Coussens, PhD, professor and chair, Cell, Developmental and Cancer Biology Department; associate director, basic research, Knight Cancer Institute, Oregon Health & Sciences University, Portland; adjunct professor, University of California, San Francisco;
Jennifer Rubin Grandis, MD, professor, otolaryngology, head and neck surgery, School of Medicine, University of California, San Francisco (UCSF); associate vice chancellor, clinical and translational research, UCSF; and
Karen E. Knudsen, PhD, director, Sidney Kimmel Cancer Center; chair and Hilary Koprowski endowed professor, Department of Cancer Biology; professor, Departments of Cancer Biology, Urology, Radiation Oncology, and Medical Oncology, Thomas Jefferson University, Philadelphia.
Press registration for the AACR Annual Meeting 2016 is free to qualified journalists and public information officers. Click here for more information.
Follow the AACR Annual Meeting 2016 on Twitter: #AACR16